Search Results 861-870 of 17398 for alopecia

1. Etiology, Prevention and Therapy Navigation of Cancer - Mayo Clinic

   The purpose of this study is to evaluate the integration of cancer pan-genetic testing into a cancer clinical practice and understand both its use and effect in ...

2. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors - Mayo Clinic

   Patients should have resolution of any toxic effects of prior therapy (except alopecia and fatigue) to National Cancer Institute (NCI) CTCAE, version 5.0, grade ...

3. A Study to Determine the Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies - Mayo Clinic

   03 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria with the exception of alopecia. Subjects with irreversible toxicity that is not ...

4. A Study to Evaluate Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol) - Mayo Clinic

   Acute effects of any prior therapy resolved to baseline severity or to Common Terminology Criteria for Adverse Events (CTCAE) grade ≤ 1 (except for alopecia, ...

5. A Study of Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumors that are Recurrent or Cannot Be Removed by Surgery - Mayo Clinic

   4.0 of prior chemotherapy regardless of interval since last treatment except alopecia and neuropathy; Requiring blood product support; Patient has CNS ...

6. Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer - Mayo Clinic

   ... alopecia and oxaliplatin induced neurotoxicity ≤ grade 2; Albumin levels > 2.5; Any of the following: Pregnant women; Nursing women; Men or women of ...

7. Nutrition and healthy eating Nutrition basics - Mayo Clinic

   You can master healthy eating by learning how to plan meals and shop smart, and by practicing healthy-cooking techniques.

8. https://www.mayoclinic.org/spanish_patient_consumer_video.xml

9. https://www.mayoclinic.org/arabic_patient_consumer_video.xml

10. Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction - Mayo Clinic

    ... alopecia, unless approved by the principal investigator; biologics or immunotherapy will not be allowed within 28 days prior to, or during, romidepsin ...